MX2020007266A - Moleculas del receptor quimerico de engullido y metodos de uso. - Google Patents
Moleculas del receptor quimerico de engullido y metodos de uso.Info
- Publication number
- MX2020007266A MX2020007266A MX2020007266A MX2020007266A MX2020007266A MX 2020007266 A MX2020007266 A MX 2020007266A MX 2020007266 A MX2020007266 A MX 2020007266A MX 2020007266 A MX2020007266 A MX 2020007266A MX 2020007266 A MX2020007266 A MX 2020007266A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- receptor molecules
- chimeric engulfment
- engulfment receptor
- molecules
- Prior art date
Links
- 230000000242 pagocytic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4612—B-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0635—B lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Abstract
La presente descripción se refiere a moléculas del receptor quimérico de engullido, a células hospedera modificadas para incluir las moléculas fagocíticas de engullido y métodos para preparar y usar tales moléculas de receptores y células modificadas.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762563615P | 2017-09-26 | 2017-09-26 | |
US201862649529P | 2018-03-28 | 2018-03-28 | |
US201862652822P | 2018-04-04 | 2018-04-04 | |
PCT/US2018/052297 WO2019067328A1 (en) | 2017-09-26 | 2018-09-21 | CHIMERIC ENGINEERING RECEPTOR MOLECULES AND METHODS OF USE |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020007266A true MX2020007266A (es) | 2020-09-07 |
Family
ID=64744922
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020007266A MX2020007266A (es) | 2017-09-26 | 2018-09-21 | Moleculas del receptor quimerico de engullido y metodos de uso. |
Country Status (11)
Country | Link |
---|---|
US (1) | US11708423B2 (es) |
EP (1) | EP3688032A1 (es) |
JP (2) | JP7286658B2 (es) |
KR (1) | KR20200100598A (es) |
CN (1) | CN111386284A (es) |
AU (1) | AU2018341244A1 (es) |
CA (1) | CA3073421A1 (es) |
IL (1) | IL272803A (es) |
MX (1) | MX2020007266A (es) |
RU (1) | RU2020114641A (es) |
WO (1) | WO2019067328A1 (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170151281A1 (en) | 2015-02-19 | 2017-06-01 | Batu Biologics, Inc. | Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer |
EP4089116A1 (en) | 2016-09-27 | 2022-11-16 | Cero Therapeutics, Inc. | Chimeric engulfment receptor molecules |
MX2020007266A (es) | 2017-09-26 | 2020-09-07 | Cero Therapeutics Inc | Moleculas del receptor quimerico de engullido y metodos de uso. |
JP7444781B2 (ja) * | 2018-03-28 | 2024-03-06 | セロ・セラピューティクス・インコーポレイテッド | 細胞免疫療法組成物およびその使用 |
EP3774864A1 (en) * | 2018-03-28 | 2021-02-17 | Cero Therapeutics, Inc. | Chimeric engulfment receptors and uses thereof for neurodegenerative diseases |
WO2019191334A1 (en) * | 2018-03-28 | 2019-10-03 | Cero Therapeutics, Inc. | Chimeric tim4 receptors and uses thereof |
EP3876977A1 (en) | 2018-11-06 | 2021-09-15 | The Regents Of The University Of California | Chimeric antigen receptors for phagocytosis |
US11013764B2 (en) | 2019-04-30 | 2021-05-25 | Myeloid Therapeutics, Inc. | Engineered phagocytic receptor compositions and methods of use thereof |
WO2021046243A2 (en) | 2019-09-03 | 2021-03-11 | Myeloid Therapeutics, Inc. | Methods and compositions for genomic integration |
WO2021067875A1 (en) * | 2019-10-03 | 2021-04-08 | Cero Therapeutics, Inc. | Chimeric tim4 receptors and uses thereof |
US10980836B1 (en) | 2019-12-11 | 2021-04-20 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods of manufacturing and use thereof |
WO2022036265A1 (en) * | 2020-08-14 | 2022-02-17 | Cero Therapeutics, Inc. | Chimeric tim receptors and uses thereof |
WO2022036287A1 (en) * | 2020-08-14 | 2022-02-17 | Cero Therapeutics, Inc. | Anti-cd72 chimeric receptors and uses thereof |
CN112194726B (zh) * | 2020-09-02 | 2023-06-23 | 沣潮医药科技(上海)有限公司 | 用于病理性蛋白聚集物清除的嵌合抗原受体及其应用 |
AU2021376354A1 (en) | 2020-11-04 | 2023-06-22 | Myeloid Therapeutics, Inc. | Engineered chimeric fusion protein compositions and methods of use thereof |
EP4247856A1 (en) * | 2020-11-18 | 2023-09-27 | Carina Biotech Pty Ltd | Chimeric antigen receptor t cell and method |
Family Cites Families (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5019368A (en) | 1989-02-23 | 1991-05-28 | Cancer Biologics, Inc. | Detection of necrotic malignant tissue and associated therapy |
US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
TW225528B (es) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
US5641863A (en) | 1993-09-30 | 1997-06-24 | University Of Pennsylvania | Chimeric IgG Fc receptors |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
TR199800012T1 (xx) | 1995-07-06 | 1998-04-21 | Novartis Ag | Piroloprimidinler ve preparasyon i�in tatbikler. |
GB9518220D0 (en) | 1995-09-06 | 1995-11-08 | Medical Res Council | Checkpoint gene |
US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
BR9708640B1 (pt) | 1996-04-12 | 2013-06-11 | inibidores irreversÍveis de tirosina-cinases e composiÇço farmacÊutica compreendendo os mesmo. | |
CA2258548C (en) | 1996-06-24 | 2005-07-26 | Pfizer Inc. | Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases |
CA2265630A1 (en) | 1996-09-13 | 1998-03-19 | Gerald Mcmahon | Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders |
EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
JPH10234372A (ja) | 1997-02-27 | 1998-09-08 | Boehringer Mannheim Corp | キメラ受容体を有する細胞とその作成方法、並びに その利用 |
CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
US20020004041A1 (en) | 1999-02-19 | 2002-01-10 | Albert Matthew L. | Methods for abrogating a cellular immune response |
EP1257584B2 (en) | 2000-02-24 | 2013-03-06 | Washington University St. Louis | Humanized antibodies that sequester amyloid beta peptide |
NZ521509A (en) | 2000-03-08 | 2005-10-28 | Nat Jewish Med & Res Center | Phosphatidylserine receptor from human, mouse, drosophila and caenorhabditis, its homologue or antibody for reducing inflammation, treating autoimmune disease and increasing anti-tumour immunity |
US20020025319A1 (en) | 2000-03-14 | 2002-02-28 | Peter Brams | Antibodies that bind phosphatidyl serine and a method of their use |
US20030072743A1 (en) | 2000-05-05 | 2003-04-17 | Matthew Albert | Genetic manipulation of phagocytes for modulation of antigen processing and the immune response therefrom |
US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
US8709412B2 (en) | 2001-06-29 | 2014-04-29 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of TIM receptor activity in combination with cytoreductive therapy |
CA2452196A1 (en) | 2001-06-29 | 2003-01-09 | The Board Of Trustees Of The Leland Stanford Junior University | T cell regulatory genes and methods of use thereof |
IL162734A0 (en) | 2002-02-01 | 2005-11-20 | Ariad Gene Therapeutics Inc | Phosphorus-containing compounds & uses thereof |
US20060002940A1 (en) | 2002-03-15 | 2006-01-05 | Jennifer Stevenson | Method of immunotherapy |
US7247303B2 (en) | 2002-07-15 | 2007-07-24 | Board Of Regents, The University Of Texas System | Selected antibody CDRs for binding to aminophospholipids |
AU2003209753A1 (en) | 2003-01-27 | 2004-08-23 | Crucell Holland B.V. | Internalising human binding molecules against cd72 |
WO2005019429A2 (en) | 2003-08-22 | 2005-03-03 | Potentia Pharmaceuticals, Inc. | Compositions and methods for enhancing phagocytosis or phagocyte activity |
US7674599B2 (en) | 2003-11-08 | 2010-03-09 | Elan Pharmaceuticals, Inc. | Methods of using antibodies to detect alpha-synuclein in fluid samples |
TW200539890A (en) | 2004-03-12 | 2005-12-16 | Brigham & Womens Hospital | Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function |
JP2007530560A (ja) | 2004-03-24 | 2007-11-01 | テロス ファーマシューティカルズ, インコーポレイテッド | ワクチンに対する免疫応答を向上させるためのアジュバントおよび使用方法 |
GB0414055D0 (en) | 2004-06-23 | 2004-07-28 | Univ Edinburgh | Specific binding members and uses thereof |
CA2591914C (en) | 2005-01-24 | 2017-04-25 | Board Of Regents, The University Of Texas System | Fc-fusion constructs binding to phosphatidylserine and their therapeutic use |
US20060257359A1 (en) | 2005-02-28 | 2006-11-16 | Cedric Francois | Modifying macrophage phenotype for treatment of disease |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
MY169492A (en) | 2006-03-23 | 2019-04-15 | Bioarctic Neuroscience Ab | Improved protofibril selective antibodies and the use thereof |
PL2046833T3 (pl) | 2006-07-14 | 2014-01-31 | Ac Immune Sa | Humanizowane przeciwciało przeciw amyloidowi beta |
WO2008042814A2 (en) | 2006-09-29 | 2008-04-10 | California Institute Of Technology | Mart-1 t cell receptors |
EP2205242B1 (en) | 2007-09-12 | 2015-04-15 | Genentech, Inc. | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use |
WO2009055730A1 (en) | 2007-10-25 | 2009-04-30 | Genentech, Inc. | Process for making thienopyrimidine compounds |
HUE025150T2 (en) | 2008-12-19 | 2016-01-28 | Biogen Int Neuroscience Gmbh | Human anti-alpha-synuclein autoantibodies |
KR101754433B1 (ko) | 2009-05-08 | 2017-07-05 | 백시넥스 인코포레이티드 | 항-cd100 항체 및 이의 사용 방법 |
WO2011085070A2 (en) | 2010-01-06 | 2011-07-14 | Virginia Tech Intellectual Properties, Inc. | Methods and compositions to improve the health of plants, animals and microbes by manipulating protein entry into symbionts and their hosts |
US20130071414A1 (en) | 2011-04-27 | 2013-03-21 | Gianpietro Dotti | Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies |
US10391126B2 (en) | 2011-11-18 | 2019-08-27 | Board Of Regents, The University Of Texas System | CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA |
WO2013192294A1 (en) | 2012-06-20 | 2013-12-27 | Boston 3T Biotechnologies, Inc. | Cellular therapies for treating and preventing cancers and other immune system disorders |
BR112015002816A8 (pt) | 2012-08-20 | 2023-04-18 | Hutchinson Fred Cancer Res | Método e composições para imunoterapia celular |
EP2906684B8 (en) | 2012-10-10 | 2020-09-02 | Sangamo Therapeutics, Inc. | T cell modifying compounds and uses thereof |
US20140162290A1 (en) | 2012-11-22 | 2014-06-12 | Riken | Probe for detecting dead cell |
WO2015066262A1 (en) | 2013-11-04 | 2015-05-07 | Trustees Of Dartmouth College | Methods for preventing toxicity of adoptive cell therapy |
CA2938887C (en) | 2014-02-14 | 2023-04-11 | Laurence J. N. Cooper | Chimeric antigen receptors and methods of making |
EP3149031B1 (en) | 2014-05-29 | 2019-12-18 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Anti-human papillomavirus 16 e7 t cell receptors |
TWI734975B (zh) | 2014-06-27 | 2021-08-01 | 美商C2N醫療診斷有限責任公司 | 人類化抗-tau抗體 |
EP3660042B1 (en) | 2014-07-31 | 2023-01-11 | Novartis AG | Subset-optimized chimeric antigen receptor-containing t-cells |
ES2891332T3 (es) | 2014-09-17 | 2022-01-27 | Novartis Ag | Direccionamiento a células citotóxicas con receptores quiméricos para la inmunoterapia adoptiva |
WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
US20170151281A1 (en) * | 2015-02-19 | 2017-06-01 | Batu Biologics, Inc. | Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer |
WO2016176639A1 (en) | 2015-04-30 | 2016-11-03 | University Of Southern California | Secretory tnt car cell immunotherapy |
CA2986254A1 (en) | 2015-05-18 | 2016-11-24 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
WO2017011316A1 (en) | 2015-07-10 | 2017-01-19 | The Trustees Of The University Of Pennsylvania | Treatment of a canine cd20 positive disease or condition using a canine cd20-specific chimeric antigen receptor |
KR20180028533A (ko) * | 2015-07-28 | 2018-03-16 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 키메릭 항원 수용체를 발현하는 변형된 단핵세포/대식세포 및 그의 용도 |
EP3202792A4 (en) | 2015-08-07 | 2018-02-21 | Shenzhen In Vivo Biomedicine Technology Limited Company | Chimeric antigen receptor containing intracellular domain of toll-like receptor |
US11352439B2 (en) | 2015-08-13 | 2022-06-07 | Kim Leslie O'Neill | Macrophage CAR (MOTO-CAR) in immunotherapy |
EP3334764A2 (en) | 2015-10-13 | 2018-06-20 | Brigham Young University | Macrophage chimeric antigen receptor (moto-car) in imunotherapy |
MA44314A (fr) | 2015-11-05 | 2018-09-12 | Juno Therapeutics Inc | Récepteurs chimériques contenant des domaines induisant traf, et compositions et méthodes associées |
US11034739B2 (en) | 2015-11-13 | 2021-06-15 | The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada | Ligand-guided phagocytosis based therapy for treatment of Alzheimer's disease and other neurodegenerative diseases |
US20180186855A1 (en) | 2016-03-23 | 2018-07-05 | Alector Llc | Chimeric receptors and methods of use thereof |
US10875919B2 (en) * | 2016-04-26 | 2020-12-29 | Alector Llc | Chimeric receptors and methods of use thereof |
WO2017205747A1 (en) | 2016-05-27 | 2017-11-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Flt3-specific chimeric antigen receptors and methods using same |
CN107522786A (zh) | 2016-06-20 | 2017-12-29 | 深圳市体内生物医药科技有限公司 | 一种分子、表达其的细胞及其制备方法和用途 |
WO2018031419A1 (en) | 2016-08-12 | 2018-02-15 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for enhancing immunogenic cross-presentation of tumor antigens |
EP4089116A1 (en) | 2016-09-27 | 2022-11-16 | Cero Therapeutics, Inc. | Chimeric engulfment receptor molecules |
US11541076B2 (en) | 2017-01-13 | 2023-01-03 | Celdara Medical, Llc | Chimeric antigen receptors targeting TIM-1 |
WO2018212770A1 (en) | 2017-05-17 | 2018-11-22 | Thunder Biotech Inc. | Transgenic macrophages, chimeric antigen receptors, and associated methods |
US10415017B2 (en) | 2017-05-17 | 2019-09-17 | Thunder Biotech, Inc. | Transgenic macrophages, chimeric antigen receptors, and associated methods |
WO2018220224A1 (en) | 2017-06-02 | 2018-12-06 | Medirista Biotechnologies Ab | Lipid-related antigens and antibodies directed against them |
MX2020007266A (es) | 2017-09-26 | 2020-09-07 | Cero Therapeutics Inc | Moleculas del receptor quimerico de engullido y metodos de uso. |
WO2019079529A1 (en) | 2017-10-17 | 2019-04-25 | The Translational Genomics Research Institute | TREM2 AGONISTS FOR STIMULATING MICROGLIA AND IDENTIFICATION METHODS |
GB201717974D0 (en) | 2017-10-31 | 2017-12-13 | Univ Court Of The Univ Of Aberdeen | Modified receptors |
JP2021502114A (ja) | 2017-11-10 | 2021-01-28 | キネオ メディカル テクノロジー カンパニー リミテッド | 改変された免疫細胞およびその使用 |
US20200399354A1 (en) | 2018-02-09 | 2020-12-24 | The Trustees Of Dartmouth College | Chimeric antigen receptors for treatment of neurodegenerative diseases and disorders |
EP3774864A1 (en) | 2018-03-28 | 2021-02-17 | Cero Therapeutics, Inc. | Chimeric engulfment receptors and uses thereof for neurodegenerative diseases |
CA3093969A1 (en) | 2018-03-28 | 2019-10-03 | Cero Therapeutics, Inc. | Expression vectors for chimeric engulfment receptors, genetically modified host cells, and uses thereof |
WO2019191334A1 (en) | 2018-03-28 | 2019-10-03 | Cero Therapeutics, Inc. | Chimeric tim4 receptors and uses thereof |
JP7444781B2 (ja) | 2018-03-28 | 2024-03-06 | セロ・セラピューティクス・インコーポレイテッド | 細胞免疫療法組成物およびその使用 |
WO2019246563A1 (en) | 2018-06-22 | 2019-12-26 | Kite Pharma, Inc. | Chimeric transmembrane proteins and uses thereof |
US20230158071A1 (en) | 2018-12-07 | 2023-05-25 | Crage Medical Co., Limited | Tumor combined immunotherapy |
MX2021013355A (es) | 2019-04-30 | 2022-02-21 | Myeloid Therapeutics Inc | Composiciones de proteínas de fusión quiméricas modificadas y métodos de uso de las mismas. |
CA3145877A1 (en) | 2019-07-03 | 2021-01-07 | The Regents Of The University Of California | Immunotherapy targeting cell surface marker cd72 for the treatment of b-cell malignancies |
WO2021067875A1 (en) | 2019-10-03 | 2021-04-08 | Cero Therapeutics, Inc. | Chimeric tim4 receptors and uses thereof |
US10980836B1 (en) | 2019-12-11 | 2021-04-20 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods of manufacturing and use thereof |
US20210253696A1 (en) | 2020-01-21 | 2021-08-19 | Cero Therapeutics, Inc. | Bivalent chimeric engulfment receptors and uses thereof |
WO2022036265A1 (en) | 2020-08-14 | 2022-02-17 | Cero Therapeutics, Inc. | Chimeric tim receptors and uses thereof |
WO2022036287A1 (en) | 2020-08-14 | 2022-02-17 | Cero Therapeutics, Inc. | Anti-cd72 chimeric receptors and uses thereof |
WO2022036285A1 (en) | 2020-08-14 | 2022-02-17 | Cero Therapeutics, Inc. | Compositions and methods for treating cancer with chimeric tim receptors in combination with inhibitors of poly (adp-ribose) polymerase |
WO2023010097A1 (en) | 2021-07-28 | 2023-02-02 | Cero Therapeutics, Inc. | Chimeric tim4 receptors and uses thereof |
-
2018
- 2018-09-21 MX MX2020007266A patent/MX2020007266A/es unknown
- 2018-09-21 KR KR1020207008130A patent/KR20200100598A/ko not_active Application Discontinuation
- 2018-09-21 AU AU2018341244A patent/AU2018341244A1/en not_active Abandoned
- 2018-09-21 CA CA3073421A patent/CA3073421A1/en active Pending
- 2018-09-21 WO PCT/US2018/052297 patent/WO2019067328A1/en unknown
- 2018-09-21 US US16/646,530 patent/US11708423B2/en active Active
- 2018-09-21 EP EP18822166.7A patent/EP3688032A1/en active Pending
- 2018-09-21 RU RU2020114641A patent/RU2020114641A/ru unknown
- 2018-09-21 JP JP2020538755A patent/JP7286658B2/ja active Active
- 2018-09-21 CN CN201880076426.1A patent/CN111386284A/zh active Pending
-
2020
- 2020-02-20 IL IL272803A patent/IL272803A/en unknown
-
2023
- 2023-05-24 JP JP2023085311A patent/JP2023120201A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3073421A1 (en) | 2019-04-04 |
US11708423B2 (en) | 2023-07-25 |
EP3688032A1 (en) | 2020-08-05 |
RU2020114641A (ru) | 2021-10-27 |
JP7286658B2 (ja) | 2023-06-05 |
US20200308305A1 (en) | 2020-10-01 |
RU2020114641A3 (es) | 2022-03-03 |
WO2019067328A1 (en) | 2019-04-04 |
AU2018341244A1 (en) | 2020-03-05 |
JP2023120201A (ja) | 2023-08-29 |
KR20200100598A (ko) | 2020-08-26 |
IL272803A (en) | 2020-04-30 |
JP2020534871A (ja) | 2020-12-03 |
CN111386284A (zh) | 2020-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019003489A (es) | Moleculas del receptor de envolvimiento quimerico. | |
MX2020007266A (es) | Moleculas del receptor quimerico de engullido y metodos de uso. | |
PH12019502283A1 (en) | Anti-lag3 antibodies | |
PH12018500711A1 (en) | Anti-pd1 antibodies and methods of use | |
MX2020009649A (es) | Anticuerpos monoclonales contra bcma. | |
PH12016501763A1 (en) | Multispecific antibodies | |
WO2016100985A3 (en) | Chimeric antigen receptors and methods of use thereof | |
NZ733055A (en) | Anti-c10orf54 antibodies and uses thereof | |
MX2019000643A (es) | Receptores de antigenos quimericos y metodos de uso. | |
PH12018500707A1 (en) | Anti-human cd19 antibodies with high affinity | |
MX2017003478A (es) | Anticuerpos anti-fgfr2/3 y metodos para su uso. | |
SG10201803042PA (en) | Anti-tim-3 antibodies | |
EP4299595A3 (en) | Compositions and methods related to engineered fc constructs | |
MY191581A (en) | Anti-pd-1 antibodies | |
MX2015012334A (es) | Metodos y composiciones para el control de malezas. | |
SG10201808259TA (en) | Anti-jagged1 antibodies and methods of use | |
SG10201808835QA (en) | Anti-siglec-8 antibodies and methods of use thereof | |
NZ761537A (en) | Anti-human ox40l antibodies, uses & methods | |
MX2016014862A (es) | Her3 / her2 anticuerpos biespecificos que se unen a la horquilla beta de her3 y al dominio ii de her2. | |
PH12018502137A1 (en) | Anti-complement factor bb antibodies and uses thereof | |
MY182924A (en) | Enzyme compositions and uses thereof | |
MX2016009590A (es) | Composiciones de apilimod y métodos para usar las mismas. | |
MY193650A (en) | Extracellular matrix compositions | |
MX2022015258A (es) | Anticuerpos anti-cxcr5 y composiciones y usos de los mismos. | |
MX2017000142A (es) | Celulas estromales mesenquimatosas para tratar el sindrome de respuesta inflamatoria sistemica. |